Elthrocin Tablet Special Precautions

Risk-benefit should be considered when the following medical problems exist:
Cardiac arrhythmias, history of, or QT prolongation: Patients with a history of cardiac arrhythmias or QT prolongation may be at risk for arrhythmias or torsades de pointes while receiving high doses of erythromycin.
Loss of hearing: Patients with a history of hearing loss may be at increased risk of further hearing loss, especially if the patient has renal or hepatic function impairment, is elderly, and is receiving high doses of erythromycin.
Liver impairment/hepatotoxic agents: Since erythromycin is excreted principally in the bile, caution should be exercised when administering it to patients with impaired liver function or receiving hepatotoxic agents.
Superinfection: The rare possibility of superinfection, caused by overgrowth of non-susceptible bacteria or fungi should be borne in mind during prolonged or repeated therapy, especially when other antibacterial agents are being employed simultaneously.
Porphyria: Erythromycin was considered to be unsafe in patients with acute porphyria because it has been associated with acute attacks.
Use in Pregnancy: There is no evidence that the use of erythromycin is hazardous in human pregnancy though it does cross the placental barrier. Animal studies have also revealed no hazard.
Use in Lactation: Erythromycin reaches concentrations in human milk higher than those in maternal plasma. However, problems in humans have not been documented.
Use in Children: Apart from reduced dosage no special precautions are required.
Use in Elderly: No special precautions are required in elderly patients with normal liver function.